Licensing · Latin America · Announced 11 May 2022
Shanghai Henlius Biotech → Eurofarma
Henlius licensed Brazil's Eurofarma to develop, make and sell its rituximab, trastuzumab and bevacizumab biosimilars in 16 Latin American countries for up to US$50.5 million, including US$4.5 million upfront.
Parties: Shanghai Henlius Biotech (China) → Eurofarma (Brazil)
- Deal type
- Licensing
- Value
- $50.5m
- Territory
- 16 Latin American countries; exclusive by product (incl. Mexico, Chile, Argentina), semi-exclusive in Brazil
- Therapeutic area
- Oncology
- Assets
- HANLIKANG (rituximab); HANQUYOU (trastuzumab); HANBEITAI (bevacizumab)
- Announced
- 11 May 2022
Our analysis
Why this matters
Shanghai Henlius Biotech and Eurofarma signed a license and collaboration agreement, announced on 11 May 2022, for development, manufacturing and commercialisation of three Henlius biosimilars in 16 Latin American countries: HANLIKANG (rituximab), HANQUYOU (trastuzumab) and HANBEITAI (bevacizumab). The deal is worth up to US$50.5 million, including US$4.5 million upfront.
Rights are exclusive by product: rituximab in 12 countries, trastuzumab in 11 and bevacizumab in 15, with examples including Mexico, Chile, Argentina, Guatemala, Panama and Ecuador, and semi-exclusive in Brazil.
The full analysis is free to read with a work email on this page.
Source: Henlius press release